Europe CRO Services Market: Growth Trends, Drivers, and Outlook
The Europe CRO services market has emerged as a critical pillar supporting the region’s pharmaceutical and biotechnology innovation ecosystem. Contract Research Organizations (CROs) offer research-based services on a contract basis to pharmaceutical, biotech, and medical device companies, as well as government research bodies, covering activities such as chemistry, manufacturing and controls (CMC), preclinical research, clinical trials, post-marketing surveillance, and laboratory services. As pharmaceutical and biotech firms increasingly look to outsource research and development functions, the demand for specialized, cost-effective CRO partnerships continues to expand across the continent.
Market Size and Growth Trajectory
The market was valued at USD 19.68 billion in 2022, according to Fortune Business Insight, and is projected to grow from USD 21.65 billion in 2023 to USD 39.55 billion by 2030, registering a compound annual growth rate (CAGR) of 9.0% during the forecast period, according to Fortune Business Insight. This steady expansion reflects rising investments in outsourced research across Europe, driven by rapid technological advancements, growing urbanization, and the increasing complexity of drug and device development pipelines.
Pandemic Impact and Recovery
The COVID-19 pandemic initially slowed market momentum due to constrained healthcare resources and a temporary decline in drug development activity. However, the market rebounded strongly in 2021 as clinical trial volumes surged and demand grew for novel therapeutics addressing chronic diseases. Pharmaceutical companies sharpened their focus on R&D and expanded manufacturing capacity for COVID-19 diagnostics and vaccines, often partnering with CROs to accelerate timelines. A notable example cited is ICON plc’s January 2021 partnership with Pfizer and BioNTech to support clinical trial services for their COVID-19 vaccine program. Additionally, the European Medicines Agency recommended authorization for 97 new medicines in 2020, including 39 new active substances, reflecting heightened R&D output. Overall, the pandemic’s impact on the broader CRO services sector led to an estimated 3.4% increase in revenues in 2020, according to Fortune Business Insight.
Key Market Drivers
Several structural factors are propelling market growth. The rising prevalence of chronic diseases—including cancer, Alzheimer’s, and cardiovascular conditions—is a primary driver. Europe accounts for 22.8% of global cancer cases and 19.6% of cancer deaths despite representing only 9.7% of the global population, according to Fortune Business Insight. In Germany alone, there were over 2.18 million prevalent cancer cases over a recent five-year span, with 628,519 new cases reported in 2020. Dementia cases in the region, reported at 10.5 million in 2021, are expected to climb to 18.7 million by 2050, according to Fortune Business Insight, further amplifying demand for novel treatments and outsourced R&D.
Europe’s robust biotechnology foundation also supports market expansion. Germany alone hosted around 500 pharmaceutical companies in 2019, according to Fortune Business Insight, combining domestic firms and international subsidiaries. The number of drug candidates in clinical development across participating biotech companies rose from 178 in 2008 to 386 in 2018, with average R&D investment per company reaching approximately USD 10.2 million. Germany’s pharmaceutical sector revenue grew 5.7% to reach USD 53.0 billion in 2019, ranking it the world’s fourth-largest pharmaceutical market after the U.S., China, and Japan, according to Fortune Business Insight.
Market Restraints
Despite favorable growth conditions, the market faces a notable restraint: a shortage of skilled professionals. As CROs compete with pharmaceutical, biotech, and academic institutions for experienced scientists, smaller analytical testing providers often struggle to offer competitive compensation. The scarcity is particularly acute in laboratory roles—the U.K. alone will require approximately 700,000 lab technicians by 2030 to sustain its economy, according to Fortune Business Insight. A 2019 survey found that over 50% of German companies viewed the skills shortage as the greatest threat to business development, a challenge further compounded by pandemic-related disruptions to workforce training.
Segmentation Insights
By service type, the clinical segment dominated the market in 2022, fueled by the high volume of clinical trials conducted across the region—65,572 trials were registered in Europe in 2019 alone, according to Fortune Business Insight. Within early phase development services, the preclinical segment held the second-largest share, benefiting from pharmaceutical companies’ growing preference for outsourcing to manage fixed and variable costs.
By application, oncology led the market given the high burden of cancer across Europe, while cardiology also registered a substantial share, driven by the roughly 3.9 million annual deaths from cardiovascular disease in the broader European region. By end-user, pharmaceutical and biotech companies represented the dominant segment, as these firms increasingly outsource therapeutic development to optimize cost structures, while medical device companies are expected to post a comparatively higher CAGR following the implementation of the EU Medical Devices Regulation (MDR) in May 2022.
Regional Insights
Among European sub-regions, the U.K. led the market in 2022 with a valuation of USD 4.53 billion, according to Fortune Business Insight, supported by a strong concentration of CROs, a high volume of registered clinical trials, and a well-regarded National Health Service infrastructure. Germany, meanwhile, is projected to post the highest CAGR during the forecast period, owing to its diversified contract research landscape and strong academic-clinical research base.
Competitive Landscape
The market remains competitive, featuring major players such as IQVIA, ICON plc, Pharmaceutical Product Development (PPD), and Laboratory Corporation of America Holdings, alongside PSI, PHASTAR, and Oy 4Pharma Ltd. Recent developments include Thermo Fisher Scientific’s completed acquisition of PPD in December 2021, LabCorp’s acquisition of Toxikon Corporation the same month, and Parexel’s October 2021 partnership with Kyoto University Hospital to broaden its clinical research footprint.
Conclusion
With sustained R&D investment, an aging population facing rising chronic disease burdens, and a mature biotechnology ecosystem, Europe’s CRO services market is well-positioned for continued expansion through 2030, even as it navigates workforce shortages and evolving regulatory frameworks.
What’s Driving Japan’s Market? Discover the Latest “Europe CRO Services Market” Insights
https://www.fortunebusinessinsights.com/jp/%E6%AC%A7%E5%B7%9Ecro%E3%82%B5%E3%83%BC%E3%83%93%E3%82%B9%E5%B8%82%E5%A0%B4-106584